A phase 1 dose escalation study of a new ALK inhibitor, CH5424802/RO5424802, in ALK+ non-small cell lung cancer (NSCLC) patients who have failed crizotinib (AF-002JG/NP28761, NCT01588028) Meeting Abstract
| Authors: | Gadgeel, S.; Ou, S. H.; Chiappori, A. A.; Riely, G.; Lee, R. M.; Garcia, L.; Sato, J.; Yokoyama, S.; Tanaka, T.; Gandhi, L. |
| Abstract Title: | A phase 1 dose escalation study of a new ALK inhibitor, CH5424802/RO5424802, in ALK+ non-small cell lung cancer (NSCLC) patients who have failed crizotinib (AF-002JG/NP28761, NCT01588028) |
| Meeting Title: | 15th World Conference on Lung Cancer (IASLC) |
| Keywords: | phase i; ch5424802; alk-inhibitor; crizotinib-failure |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 8 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2013 Oct 27-31 |
| Meeting Location: | Sydney, Australia |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2013-11-01 |
| Start Page: | S199 |
| Language: | English |
| ACCESSION: | WOS:000339624900247 |
| PROVIDER: | wos |
| DOI: | 10.1097/01.JTO.0000438438.14562.c8 |
| Notes: | Meeting Abstract: O16.06 -- Source: Wos |
